HOXC10 promotes tumour metastasis by regulating the EMT-related gene Slug in ovarian cancer
metastatic symptoms. Recent studies have shown that HOX genes are crucial in tumour progression, but the underlying mechanisms remain unclear. Here, HOXC10 expression was examined in ovarian cancer tissues. The function of HOXC10 in ovarian cancer metastasis was investigated in vitroand via intraperitoneal injection in vivo. A total of 158 ovarian cancer patients with adequate records were enrolled for analysis. HOXC10 was associated with metastasis and poor prognosis in ovarian cancer. In vitro, HOXC10 overexpression promoted ovarian cancer cell migration.
Moreover, HOXC10 positively regulated Slug expression, altering the migration ability of cancer cells. Furthermore, our study showed that miR-222-3p was a suppressor of HOXC10. In vivo, a decrease in hepatic metastasis was seen in xenograft mice harbouring tumours with stable HOXC10 overexpression after miR-222-3p agomir (an overexpression reagent) injection. This study provides the first evidence that HOXC10 promotes ovarian cancer metastasis by regulating the transcription of the EMT-related gene Slug. Moreover, we found that HOXC10 is regulated by miR-222-3p. These data highlight the crucial role of HOXC10 in enhancing ovarian cancer metastasis and may provide a therapeutic target for ovarian cancer.
Cancer Antigen 125 Antigen (Ascites Fluid) |
|||
| VAng-Cr3870-10kU | Creative Biolabs | 10 kU | EUR 1132.8 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE. |
|||
Cancer Antigen 125 Antigen (Human Adenocarcinoma) |
|||
| VAng-Cr3868-10kU | Creative Biolabs | 10 kU | EUR 505.2 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography. |
|||
Human carcinoembryonic antigen (CEA) antigen |
|||
| CEA15-N-100 | Alpha Diagnostics | 100 ug | EUR 270 |
Cancer Antigen CEA Antigen (Human Fluids) |
|||
| VAng-Wyb8644-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL. |
|||
Cancer Antigen 19-9 Antigen (Liver Carcinoma) |
|||
| VAng-Cr3873-10kU | Creative Biolabs | 10 kU | EUR 472.8 |
|
Description: Cancer Antigen 19-9 Antigen, Host/Source: Liver Carcinoma. The purity is detected by gel filtration and ion-exchange chromatography. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
|||
Prostate Specific Antigen Std Grade Antigen |
|||
| VAng-Cr3891-1mg | Creative Biolabs | 1 mg | EUR 604.8 |
|
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation. |
|||
Cancer Antigen 125 Antigen (Human Adenocarcinoma) (> 90%) |
|||
| VAng-Cr3869-25kU | Creative Biolabs | 25 kU | EUR 967.2 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is> 90% by SDS-PAGE. Matched Pair: HM183, HM184, HM185, HM186. |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
Cancer Antigen 19-9 Antigen (Liver Carcinoma) (> 90%) |
|||
| VAng-Cr3875-25kU | Creative Biolabs | 25 kU | EUR 885.6 |
|
Description: Cancer Antigen 19-9 Antigen, Host/Source: Liver Carcinoma. The purity is> 90% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
|||
Cancer Antigen AFP Antigen (Human Cord Blood) |
|||
| VAng-Wyb8624-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: Alpha Fetoprotein (66 kDa), Cancer antigen from Human Cord Blood, 1.73 mg/mL. |
|||
Cancer Antigen CA-125 Antigen (Human Fluids) |
|||
| VAng-Wyb8639-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: CA-125, Calibrator Grade, cancer antigen from Human Fluids, 53.26 KU/mL. |
|||
Cancer Antigen 15-3 MUC 1 Antigen (Human Milk) |
|||
| VAng-Cr3871-10kU | Creative Biolabs | 10 kU | EUR 505.2 |
|
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
|||
MPO Antigen |
|||
| E61A00501 | EnoGene | 1mg | EUR 1230 |
HAV Antigen |
|||
| E61H00101 | EnoGene | 1mg | EUR 733.2 |
HBS Antigen |
|||
| E61H00301 | EnoGene | 1mg | EUR 374.4 |
HBS Antigen |
|||
| E61H00302 | EnoGene | 1mg | EUR 374.4 |
HBe Antigen |
|||
| E61H00501 | EnoGene | 1mg | EUR 463.2 |
HBc Antigen |
|||
| E61H00701 | EnoGene | 1mg | EUR 463.2 |
AFP Antigen |
|||
| E62C002 | EnoGene | 20ug | EUR 458.4 |
HCG Antigen |
|||
| E62C004 | EnoGene | 100ug | EUR 458.4 |
CEA Antigen |
|||
| E62C010 | EnoGene | 20ug | EUR 458.4 |
CK8 Antigen |
|||
| E62C02001 | EnoGene | 20ug | EUR 458.4 |
CRP Antigen |
|||
| E64C00501 | EnoGene | 1mg | EUR 840 |
CRP Antigen |
|||
| E64C00502 | EnoGene | 1mg | EUR 840 |
CD9 Antigen |
|||
| E6TA00101 | EnoGene | 0.1mg | EUR 411.6 |
BSA Antigen |
|||
| IM112 | Cygnus Technologies | 1 ml | EUR 342 |
|
Description: BSA Antigen by Cygnus Technologies is available in Europe via Gentaur. |
|||
HSA Antigen |
|||
| IM118 | Cygnus Technologies | 1 ml | EUR 342 |
|
Description: HSA Antigen by Cygnus Technologies is available in Europe via Gentaur. |
|||
CDV Antigen |
|||
| VAng-Lsx0016-1mg | Creative Biolabs | 1 mg | EUR 1688.4 |
|
Description: Canine Distemper Virus Antigen from SL-29 cells. |
|||
Gastrointestinal Cancer Antigen (CA 19-9), antigen grade |
|||
| CA1991-N-10 | Alpha Diagnostics | 10 KU | EUR 634.8 |
S100 Antigen |
|||
| E62B003 | EnoGene | 20ug | EUR 458.4 |
CA50 Antigen |
|||
| E62C009 | EnoGene | 10KU | EUR 458.4 |
CK18 Antigen |
|||
| E62C02101 | EnoGene | 20ug | EUR 458.4 |
CK20 Antigen |
|||
| E62C02201 | EnoGene | 20ug | EUR 458.4 |
GP73 antigen |
|||
| E62C02701 | EnoGene | 20ug | EUR 458.4 |
TP17 Antigen |
|||
| E62H00701 | EnoGene | 100ug | EUR 458.4 |
TP47 Antigen |
|||
| E62H00702 | EnoGene | 100ug | EUR 458.4 |
cTnI antigen |
|||
| E64C00101 | EnoGene | 100ug | EUR 508.8 |
cTnI antigen |
|||
| E64C00102 | EnoGene | 100ug | EUR 733.2 |
cTnC antigen |
|||
| E64C01301a | EnoGene | 20ug | EUR 411.6 |
sST2 antigen |
|||
| E64C01501 | EnoGene | 20ug | EUR 411.6 |
PAPP Antigen |
|||
| E64D00101 | EnoGene | 100ug | EUR 1425.6 |
PAPP Antigen |
|||
| E64D00102 | EnoGene | 1mg | EUR 5910 |
CD63 Antigen |
|||
| E6TA00102 | EnoGene | 0.1mg | EUR 411.6 |
CD81 Antigen |
|||
| E6TA00103 | EnoGene | 0.1mg | EUR 411.6 |
Cancer Antigen CEA Antigen (Human Metastatic Liver) |
|||
| VAng-Wyb8645-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: Carcinoembryonic Antigen, Antigen Grade, Cancer antigen from Human Metastatic Liver, 5.5 mg/mL. |
|||
CA242 Antigen |
|||
| E62C00601 | EnoGene | 50KU | EUR 2078.4 |
CA242 Antigen |
|||
| E62C00602 | EnoGene | 10KU | EUR 458.4 |
CA199 Antigen |
|||
| E62C007 | EnoGene | 10KU | EUR 458.4 |
CA199 Antigen |
|||
| E62C00701 | EnoGene | 50KU | EUR 1180.8 |
CA199 Antigen |
|||
| E62C00702 | EnoGene | 50KU | EUR 1620 |
CA125 Antigen |
|||
| E62C011 | EnoGene | 10KU | EUR 458.4 |
CA153 Antigen |
|||
| E62C012 | EnoGene | 10KU | EUR 458.4 |
EpCAM Antigen |
|||
| E64B00107 | EnoGene | 0.1mg | EUR 411.6 |
HSP70 Antigen |
|||
| E6TA00104 | EnoGene | 0.1mg | EUR 411.6 |
CD133 Antigen |
|||
| E6TA00105 | EnoGene | 0.1mg | EUR 411.6 |
CD32a Antigen |
|||
| E6TA00106 | EnoGene | 0.1mg | EUR 411.6 |
Cancer Antigen CA-125 Antigen (Human Adenocarcinoma) |
|||
| VAng-Wyb8642-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: CA-125, Calibrator Grade, Cancer antigen from Human Adenocarcinoma, 500 kIU / mL. |
|||
S100BB Antigen |
|||
| E62B00201 | EnoGene | 20ug | EUR 458.4 |
S100BB Antigen |
|||
| E62B00202 | EnoGene | 20ug | EUR 458.4 |
Giardia Trophozoite Recombinant antigen antigen 34 kDa |
|||
| 00321-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: Giardia Trophozoite Recombinant antigen antigen 34 kDa a.a. 21-280 |
|||
Giardia Trophozoite Recombinant antigen antigen 34 kDa |
|||
| 00321-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: Giardia Trophozoite Recombinant antigen antigen 34 kDa a.a. 21-280 |
|||
Cancer Antigen 19-9 Antigen (Liver Carcinoma) (High purity) |
|||
| VAng-Cr3874-25kU | Creative Biolabs | 25 kU | EUR 1033.2 |
|
Description: Cancer Antigen 19-9 Antigen, Host/Source: Liver Carcinoma. |
|||
S100A1B Antigen |
|||
| E62B00101 | EnoGene | 20ug | EUR 458.4 |
S100A1B Antigen |
|||
| E62B00102 | EnoGene | 20ug | EUR 458.4 |
Insulin Antigen |
|||
| E64I001 | EnoGene | 1mg | EUR 418.8 |
Insulin Antigen |
|||
| IM121 | Cygnus Technologies | 1 ml | EUR 342 |
|
Description: Insulin Antigen by Cygnus Technologies is available in Europe via Gentaur. |
|||
Ferritin Antigen |
|||
| E62C013 | EnoGene | 100ug | EUR 458.4 |
Ferritin Antigen |
|||
| E62C01304 | EnoGene | 100ug | EUR 458.4 |
Copeptin antigen |
|||
| E64C01601 | EnoGene | 100ug | EUR 411.6 |
Cancer Antigen AFP Antigen (Human hepatocellular carcinoma) |
|||
| VAng-Wyb8625-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: Alpha Fetoprotein, Antigen Grade, Cancer antigen from human hepatocellular carcinoma, 2.93 mg/mL. |
|||
Rotavirus Antigen |
|||
| DAGA-258 | Creative Diagnostics | 1 ml dry ice | EUR 873.6 |
Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid) |
|||
| VAng-Cr3872-10kU | Creative Biolabs | 10 kU | EUR 1363.2 |
|
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid. |
|||
Enterovirus Antigen |
|||
| 30-1984 | Fitzgerald | 1 mg | EUR 855.6 |
|
Description: Enterovirus Protein |
|||
Hydrocodone Antigen |
|||
| VAng-Cr3693-1mg | Creative Biolabs | 1 mg | EUR 967.2 |
|
Description: Hydrocodone Antigen, matched pairs: JP101, JP102 or JP103 (detection); Used for ELISA, Lateral Flow. |
|||
RV Antigen (E1) |
|||
| E61Y00101 | EnoGene | 1mg | EUR 840 |
Calprotectin Antigen |
|||
| DAG-T1230 | Creative Diagnostics | 1mg | EUR 4446 |
SS-A Antigen |
|||
| E61A00301 | EnoGene | 1mg | EUR 1230 |
SS-B Antigen |
|||
| E61A00401 | EnoGene | 1mg | EUR 1230 |
IL-2 antigen |
|||
| E6IE600106 | EnoGene | 20ug | EUR 411.6 |
IL-4 antigen |
|||
| E6IE600107 | EnoGene | 20ug | EUR 411.6 |
IL-6 antigen |
|||
| E6IE600108 | EnoGene | 20ug | EUR 411.6 |
IL-2 antigen |
|||
| E6L00106 | EnoGene | 20ug | EUR 458.4 |
IL-4 antigen |
|||
| E6L00107 | EnoGene | 20ug | EUR 458.4 |
IL-6 antigen |
|||
| E6L00108 | EnoGene | 20ug | EUR 458.4 |
Thyroglobulin Antigen |
|||
| VAng-Cr3893-1mg | Creative Biolabs | 1 mg | EUR 604.8 |
|
Description: Thyroglobulin Antigen, Host/Source: Human Thyroid Tissue. The purity is> 95% by SDS-PAGE. |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCA0228-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),APC conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC800228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF680 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC800228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF680 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC810228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF680R conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC810228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF680R conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC940228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF594 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC940228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF594 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC700228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF770 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC700228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF770 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC880228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF488A conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC880228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF488A conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC430228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF543 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC430228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF543 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC400228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF640R conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC400228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF640R conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC050228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF405M conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC050228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF405M conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCB0228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),Biotin conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCB0228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),Biotin conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCAP0228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCAP0228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCR0228-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),RPE conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCP0228-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),PerCP conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNUM0228-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6), 1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCH0228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNCH0228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNUB0228-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6), Concentration: 0.2mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNUB0228-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6), Concentration: 0.2mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC040228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF405S conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC040228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF405S conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC550228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF555 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC550228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF555 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC610228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF660R conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC610228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF660R conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC680228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF568 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC680228-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF568 conjugate, Concentration: 0.1mg/mL |
|||
HL-60 Antigen / Human Leukemia Antigen (IPO-M6) Antibody |
|||
| BNC470228-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against HL-60 Antigen / Human Leukemia Antigen (IPO-M6),CF647 conjugate, Concentration: 0.1mg/mL |
|||
Comparison between Single- and Group-housed Pregnant Sows for Direct and Indirect Physiological, Reproductive, Welfare Indicators and Gene Expression Profiling
Single- and group-housed pregnant sows were assessed during 8 weeks (4th and 8th to 14th) with regard to physiological, reproductive, welfare indicators and gene expression profiling. Compared to single-housed sows, group-housed sows had decreased non-return to estrus at 56 days after artificial insemination (AI) (83% vs 92%) and farrowing rate (78% vs 88%), respectively. Furthermore, group-housed sows showed a higher degree (p < 0.01) of advantageous physiological indicators, such as albumin (odds ratio [OR] = 4.4), alkaline phosphatase (OR = 1.5), bactericidal (OR = 3.2) and complement (OR = 24.3), and disadvantageous for alanine amino transferase (OR = 0.5), bilirubin (OR = 0.4), lysozyme (OR = 0.3) and C-reactive protein compared to single-housed.
Eighty-seven genes related to immune response were underexpressed (log fold change ≤ 1.5; p < 0.05) during the 8th to 14th weeks in the group compared to single-housed sows, which in turn showed an immunomodulatory reduction on the expression of 43 genes during the 11th to 14th compared to the 4th week. Overall, the results were interpreted as indicative of greater comfort state of the group compared to single-housed sows.
Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer
- Objectives: The purpose of this study was to investigate the association of syndecan-1 (SDC1) and KRAS molecular characteristics with patient survival in pancreatic cancer.
- Methods: Both SDC1 mRNA and methylation and KRAS mRNA and somatic mutations, as well as clinical data were retrieved from a The Cancer Genome Alta pancreatic cancer data set for survival analyses. Kyoto Encyclopedia of Gene and Genomes pathway analysis for coexpressed genes for either SDC1 or KRAS was performed, respectively.
- Results: A significantly negative correlation existed between SDC1 mRNA and DNA methylation. Patients with KRAS somatic mutations had a significantly higher SDC1 mRNA but lower methylation than those without the mutations. Compared with patients with KRASSDC1 signature, those with a high level of KRAS and SDC1 alone or both had a significantly elevated mortality. The adjusted hazard ratios (95% confidence interval) were 2.30 (1.16-4.54, P = 0.017) for KRASSDC1, 2.85 (1.48-5.49, P = 0.002) for KRASSDC1, and 2.48 (1.31-4.70, P = 0.005) for KRASSDC1, respectively. Several Kyoto Encyclopedia of Gene and Genomes pathways were shared, whereas there were distinct pathways between KRAS and SDC1 coexpressed genes.
- Conclusions: SDC1 interplays with KRAS, and targeting both KRAS and SDC1 in combination may be more beneficial to pancreatic cancer patients.
Short communication: Genome-wide identification of new reference genes for reverse-transcription quantitative PCR in Streptococcus thermophilus based on RNA-sequencing analysis
Streptococcus thermophilus, one of the most important industrial lactic acid bacteria, is widely used for the production of fermented dairy products such as yogurt and cheese. The accuracy of gene expression-based analyses (e.g., reverse-transcription quantitative real-time PCR) relies heavily on the selection of reliable reference genes (RG), which provides the basis for correctly interpreting expression data. However, many traditional RG are not stably expressed in different systems. Here we used RNA-sequencing to systematically investigate gene expression variation at the genome scale and identify more stable RG in S. thermophilus.
In total, 21 putative candidate RG were identified with variation coefficient values <10.0 based on the expression of all 1,911 genes under 4 different experimental conditions. We selected and validated 12 RG chosen from transcriptomes by using reverse-transcription quantitative real-time PCR, and ranked their expression stability by statistical algorithms geNorm and NormFinder. Compared with traditional RG 16S rRNA, genes encoding glycine-tRNA ligase subunit β GlyS and fatty acid-binding protein DegV were more stable under all 4 treatments, which have never been used as RG in S. thermophilus. Our finding provides the foundation for more precise analysis of gene expression in S. thermophilus and other lactic acid bacteria species.
PLDN antibody |
|||
| 70R-19338 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal PLDN antibody |
|||
PLDN antibody |
|||
| 70R-35798 | Fitzgerald | 100 ug | EUR 418.8 |
|
Description: Rabbit polyclonal PLDN antibody |
|||
PLDN Antibody |
|||
| DF12041 | Affbiotech | 200ul | EUR 420 |
anti- PLDN antibody |
|||
| FNab06531 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against PLDN |
|||
Pallidin Homolog (PLDN) Antibody |
|||
| 20-abx114318 | Abbexa |
|
|
Polyclonal PLDN antibody - middle region |
|||
| AMM07239G | Leading Biology | 0.05mg | EUR 633.6 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PLDN - middle region. This antibody is tested and proven to work in the following applications: |
|||
Biogenesis of Lysosomal Organelles Complex 1 Subunit 6 (PLDN) Antibody |
|||
| abx236531-100ug | Abbexa | 100 ug | EUR 577.2 |
Biogenesis of Lysosomal Organelles Complex 1 Subunit 6 (PLDN) Antibody |
|||
| abx036189-100ug | Abbexa | 100 ug | EUR 469.2 |
PLDN cloning plasmid |
|||
| CSB-CL890745HU-10ug | Cusabio | 10ug | EUR 279.6 |
|
Description: A cloning plasmid for the PLDN gene. |
|||
PLDN Blocking Peptide |
|||
| 33R-2437 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PLDN antibody, catalog no. 70R-2858 |
|||
PLDN Blocking Peptide |
|||
| 33R-6524 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PLDN antibody, catalog no. 70R-2857 |
|||
PLDN Blocking Peptide |
|||
| DF12041-BP | Affbiotech | 1mg | EUR 234 |
PLDN protein (His tag) |
|||
| 80R-2215 | Fitzgerald | 50 ug | EUR 386.4 |
|
Description: Purified recombinant Human PLDN Protein (His tag) |
|||
PLDN ELISA KIT|Human |
|||
| EF001846 | Lifescience Market | 96 Tests | EUR 826.8 |
PLDN Recombinant Protein (Rat) |
|||
| RP220886 | ABM | 100 ug | Ask for price |
PLDN Recombinant Protein (Mouse) |
|||
| RP162719 | ABM | 100 ug | Ask for price |
PLDN Recombinant Protein (Human) |
|||
| RP023749 | ABM | 100 ug | Ask for price |
Pldn ORF Vector (Rat) (pORF) |
|||
| ORF073630 | ABM | 1.0 ug DNA | EUR 607.2 |
PLDN ORF Vector (Human) (pORF) |
|||
| ORF007917 | ABM | 1.0 ug DNA | EUR 114 |
Pldn ORF Vector (Mouse) (pORF) |
|||
| ORF054241 | ABM | 1.0 ug DNA | EUR 607.2 |
Rat Pallidin(PLDN)ELISA kit |
|||
| QY-E10560 | Qayee Biotechnology | 96T | EUR 433.2 |
Human Pallidin (PLDN)ELISA kit |
|||
| 201-12-2524 | SunredBio | 96 tests | EUR 528 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
|||
Mouse Pallidin, Pldn ELISA KIT |
|||
| ELI-36376m | Lifescience Market | 96 Tests | EUR 1038 |
Human Pallidin, PLDN ELISA KIT |
|||
| ELI-21687h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse Pallidin(PLDN)ELISA kit |
|||
| QY-E21136 | Qayee Biotechnology | 96T | EUR 433.2 |
Human Pallidin(PLDN)ELISA Kit |
|||
| QY-E04062 | Qayee Biotechnology | 96T | EUR 433.2 |
Human Pallidin (PLDN)ELISA kit |
|||
| YLA3193HU-48T | Shanghai YL Biotech | 48T | EUR 435 |
Human Pallidin (PLDN)ELISA kit |
|||
| YLA3193HU-96T | Shanghai YL Biotech | 96T | EUR 562.5 |
Pldn sgRNA CRISPR Lentivector set (Rat) |
|||
| K7200301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Anti-PLDN antibody |
|||
| PAab06531 | Lifescience Market | 100 ug | EUR 426 |
Pldn 3'UTR GFP Stable Cell Line |
|||
| TU166520 | ABM | 1.0 ml | Ask for price |
PLDN 3'UTR GFP Stable Cell Line |
|||
| TU068229 | ABM | 1.0 ml | EUR 2799.6 |
Pldn 3'UTR GFP Stable Cell Line |
|||
| TU266380 | ABM | 1.0 ml | Ask for price |
PLDN sgRNA CRISPR Lentivector set (Human) |
|||
| K1664801 | ABM | 3 x 1.0 ug | EUR 406.8 |
Pldn sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3722301 | ABM | 3 x 1.0 ug | EUR 406.8 |
PLDN Protein Vector (Rat) (pPM-C-HA) |
|||
| PV294520 | ABM | 500 ng | EUR 723.6 |
PLDN Protein Vector (Rat) (pPB-C-His) |
|||
| PV294518 | ABM | 500 ng | EUR 723.6 |
PLDN Protein Vector (Rat) (pPB-N-His) |
|||
| PV294519 | ABM | 500 ng | EUR 723.6 |
PLDN Protein Vector (Rat) (pPM-C-His) |
|||
| PV294521 | ABM | 500 ng | EUR 723.6 |
PLDN Protein Vector (Human) (pPM-C-HA) |
|||
| PV031667 | ABM | 500 ng | EUR 394.8 |
PLDN Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV216964 | ABM | 500 ng | EUR 723.6 |
PLDN Protein Vector (Human) (pPB-C-His) |
|||
| PV031665 | ABM | 500 ng | EUR 394.8 |
PLDN Protein Vector (Human) (pPB-N-His) |
|||
| PV031666 | ABM | 500 ng | EUR 394.8 |
PLDN Protein Vector (Human) (pPM-C-His) |
|||
| PV031668 | ABM | 500 ng | EUR 394.8 |
PLDN Protein Vector (Mouse) (pPB-C-His) |
|||
| PV216962 | ABM | 500 ng | EUR 723.6 |
PLDN Protein Vector (Mouse) (pPB-N-His) |
|||
| PV216963 | ABM | 500 ng | EUR 723.6 |
PLDN Protein Vector (Mouse) (pPM-C-His) |
|||
| PV216965 | ABM | 500 ng | EUR 723.6 |
Pldn 3'UTR Luciferase Stable Cell Line |
|||
| TU116520 | ABM | 1.0 ml | Ask for price |
PLDN 3'UTR Luciferase Stable Cell Line |
|||
| TU018229 | ABM | 1.0 ml | EUR 2799.6 |
Pldn 3'UTR Luciferase Stable Cell Line |
|||
| TU216380 | ABM | 1.0 ml | Ask for price |
PLDN Pallidin Homolog Human Recombinant Protein |
|||
| PROTQ9UL45 | BosterBio | Regular: 10ug | EUR 380.4 |
|
Description: PLDN Human Recombinant produced in E. coli is a single polypeptide chain containing 192 amino acids (1-172) and having a molecular mass of 21.9kDa.;PLDN is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
Pldn sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7200302 | ABM | 1.0 ug DNA | EUR 184.8 |
Pldn sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7200303 | ABM | 1.0 ug DNA | EUR 184.8 |
Pldn sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7200304 | ABM | 1.0 ug DNA | EUR 184.8 |
PLDN sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1664802 | ABM | 1.0 ug DNA | EUR 184.8 |
PLDN sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1664803 | ABM | 1.0 ug DNA | EUR 184.8 |
PLDN sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1664804 | ABM | 1.0 ug DNA | EUR 184.8 |
Pldn sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3722302 | ABM | 1.0 ug DNA | EUR 184.8 |
Pldn sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3722303 | ABM | 1.0 ug DNA | EUR 184.8 |
Pldn sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3722304 | ABM | 1.0 ug DNA | EUR 184.8 |
Recombinant Human PLDN Protein, His, E.coli-1mg |
|||
| QP13077-1mg | EnQuireBio | 1mg | EUR 6301.2 |
Recombinant Human PLDN Protein, His, E.coli-2ug |
|||
| QP13077-2ug | EnQuireBio | 2ug | EUR 186 |
Recombinant Human PLDN Protein, His, E.coli-10ug |
|||
| QP13077-10ug | EnQuireBio | 10ug | EUR 241.2 |
PLDN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV629023 | ABM | 1.0 ug DNA | EUR 616.8 |
PLDN Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV629027 | ABM | 1.0 ug DNA | EUR 616.8 |
PLDN Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV629028 | ABM | 1.0 ug DNA | EUR 616.8 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K7200305 | ABM | 3 x 1.0 ug | EUR 451.2 |
PLDN sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K1664805 | ABM | 3 x 1.0 ug | EUR 451.2 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3722305 | ABM | 3 x 1.0 ug | EUR 451.2 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K7200306 | ABM | 1.0 ug DNA | EUR 200.4 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K7200307 | ABM | 1.0 ug DNA | EUR 200.4 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K7200308 | ABM | 1.0 ug DNA | EUR 200.4 |
PLDN sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K1664806 | ABM | 1.0 ug DNA | EUR 200.4 |
PLDN sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K1664807 | ABM | 1.0 ug DNA | EUR 200.4 |
PLDN sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K1664808 | ABM | 1.0 ug DNA | EUR 200.4 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3722306 | ABM | 1.0 ug DNA | EUR 200.4 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3722307 | ABM | 1.0 ug DNA | EUR 200.4 |
Pldn sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3722308 | ABM | 1.0 ug DNA | EUR 200.4 |
PLDN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV629024 | ABM | 1.0 ug DNA | EUR 616.8 |
PLDN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV629025 | ABM | 1.0 ug DNA | EUR 686.4 |
PLDN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV629026 | ABM | 1.0 ug DNA | EUR 686.4 |
PLD2 Antibody |
|||
| AF7603 | Affbiotech | 200ul | EUR 540 |
PLD1 Antibody |
|||
| AF7871 | Affbiotech | 200ul | EUR 540 |
PLD3 Antibody |
|||
| 39791-100ul | SAB | 100ul | EUR 468 |
PLD1 Antibody |
|||
| AF4765 | Affbiotech | 200ul | EUR 540 |
PLD2 Antibody |
|||
| AF6974 | Affbiotech | 100ul | EUR 420 |
PLD3 antibody |
|||
| 70R-6831 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal PLD3 antibody raised against the N terminal of PLD3 |
|||
PLD2 antibody |
|||
| 70R-7964 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Affinity purified rabbit polyclonal PLD2 antibody |
|||
PLD2 antibody |
|||
| 70R-8244 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Affinity purified rabbit polyclonal PLD2 antibody |
|||
PLD1 antibody |
|||
| 70R-31530 | Fitzgerald | 100 ug | EUR 392.4 |
|
Description: Rabbit polyclonal PLD1 antibody |
|||
PLD1 antibody |
|||
| 70R-19337 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal PLD1 antibody |
|||
PLD3 antibody |
|||
| 70R-36350 | Fitzgerald | 100 ug | EUR 418.8 |
|
Description: Rabbit polyclonal PLD3 antibody |
|||
PLD4 antibody |
|||
| 70R-35616 | Fitzgerald | 100 ug | EUR 418.8 |
|
Description: Rabbit polyclonal PLD4 antibody |
|||
PLD4 Antibody |
|||
| 34905-100ul | SAB | 100ul | EUR 302.4 |
PLD4 Antibody |
|||
| 34905-50ul | SAB | 50ul | EUR 224.4 |
PLD2 Antibody |
|||
| 46133-100ul | SAB | 100ul | EUR 302.4 |
PLD2 Antibody |
|||
| 46133-50ul | SAB | 50ul | EUR 224.4 |
PLD1 Antibody |
|||
| 45148-100ul | SAB | 100ul | EUR 302.4 |
PLD1 Antibody |
|||
| 45148-50ul | SAB | 50ul | EUR 224.4 |
PLD1 Antibody |
|||
| ABD13213 | Lifescience Market | 100 ug | EUR 525.6 |
PLD3 Antibody |
|||
| ABD13214 | Lifescience Market | 100 ug | EUR 525.6 |
PLD4 Antibody |
|||
| ABD4294 | Lifescience Market | 100 ug | EUR 525.6 |
PLD1 Antibody |
|||
| ABD7802 | Lifescience Market | 100 ug | EUR 525.6 |
PLD2 Antibody |
|||
| ABD9752 | Lifescience Market | 100 ug | EUR 525.6 |
PLD3 Antibody |
|||
| ABD9753 | Lifescience Market | 100 ug | EUR 525.6 |
PLD2 Antibody |
|||
| DF9752 | Affbiotech | 200ul | EUR 420 |
PLD3 Antibody |
|||
| DF9753 | Affbiotech | 200ul | EUR 420 |
PLD1 Antibody |
|||
| DF7802 | Affbiotech | 200ul | EUR 420 |
PLD4 Antibody |
|||
| DF4294 | Affbiotech | 200ul | EUR 420 |
PLD4 Antibody |
|||
| CSB-PA219574- | Cusabio | each | EUR 402 |
|
Description: A polyclonal antibody against PLD4. Recognizes PLD4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
PLD4 Antibody |
|||
| CSB-PA219574-100ul | Cusabio | 100ul | EUR 379.2 |
|
Description: A polyclonal antibody against PLD4. Recognizes PLD4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
PLD6 Antibody |
|||
| 1-CSB-PA836649LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD6. Recognizes PLD6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:2000-1:5000, IHC:1:20-1:200, IF:1:50-1:200 |
|||
PLD5 Antibody |
|||
| 1-CSB-PA836686LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD5. Recognizes PLD5 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
PLD4 Antibody |
|||
| 1-CSB-PA839298LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD4. Recognizes PLD4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200, IF:1:50-1:200 |
|||
PLD3 Antibody |
|||
| 1-CSB-PA008426 | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD3. Recognizes PLD3 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/5000 |
|||
PLD1 Antibody |
|||
| 1-CSB-PA030081 | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD1. Recognizes PLD1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/5000 |
|||
PLD1 Antibody |
|||
| 1-CSB-PA030082 | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD1. Recognizes PLD1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000 |
|||
PLD2 Antibody |
|||
| 1-CSB-PA030084 | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD2. Recognizes PLD2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
|||
PLD1 Antibody |
|||
| 1-CSB-PA018144GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD1. Recognizes PLD1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
|||
PLD2 Antibody |
|||
| 1-CSB-PA018145LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD2. Recognizes PLD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
PLD3 Antibody |
|||
| 1-CSB-PA018146LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD3. Recognizes PLD3 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200 |
|||
PLD1 Antibody |
|||
| 1-CSB-PA614406LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD1. Recognizes PLD1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IF; Recommended dilution: IF:1:50-1:200 |
|||
PLD4 Antibody |
|||
| 1-CSB-PA006980 | Cusabio |
|
|
|
Description: A polyclonal antibody against PLD4. Recognizes PLD4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/5000 |
|||
PLD2 antibody |
|||
| PAab10085 | Lifescience Market | 100 ug | EUR 463.2 |
PLD1 Antibody |
|||
| R30165 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: This gene encodes a phosphatidylcholine-specific phospholipase which catalyzes the hydrolysis of phosphatidylcholine in order to yield phosphatidic acid and choline. The enzyme may play a role in signal transduction and subcellular trafficking. Alternative splicing results in multiple transcript variants with both catalytic and regulatory properties. |
|||
PLD1 Antibody |
|||
| R32213 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: By somatic cell hybrid analysis, PLD1 is mapped to 3q26.31. This gene encodes a phosphatidylcholine-specific phospholipase which catalyzes the hydrolysis of phosphatidylcholine in order to yield phosphatidic acid and choline. The enzyme may play a role in signal transduction and subcellular trafficking. Alternative splicing results in multiple transcript variants with both catalytic and regulatory properties. And PLD1 disrupted association of gamma-secretase protein components, independent of PLD1catalytic activity. What's more, PLD1 regulates intracellular trafficking of beta-amyloid, distinct from its effect on gamma-secretase activity. |
|||
anti- PLD2 antibody |
|||
| FNab10085 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against PLD2 |
|||
anti- PLD1 antibody |
|||
| FNab06530 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against PLD1 |
|||
PLD2 (pY169) Antibody |
|||
| abx333307-100ul | Abbexa | 100 ul | EUR 560.4 |
PLD1 (pT147) Antibody |
|||
| abx333429-100ul | Abbexa | 100 ul | EUR 560.4 |
PLD1 antibody (Ser561) |
|||
| 70R-31529 | Fitzgerald | 100 ug | EUR 392.4 |
|
Description: Rabbit polyclonal PLD1 antibody (Ser561) |
|||